The aim of this review is to give the reader an updated overview of the relevance of PI3K/Akt/mTOR signaling activation in AML patients and to focus on small molecules which will possibly have an impact on the therapeutic arsenal we have against this disease. Here, PIK3CA is linked to acute myeloid leukemia.